OSR Holdings Secures Major $815 Million Global License Agreement for VXM01 Cancer Immunotherapy
OSR Holdings Secures Major $815 Million Global License Agreement for VXM01 Cancer Immunotherapy
OSR Holdings, Inc. has announced a definitive global exclusive license agreement with BCM Europe AG for VXM01, a Phase 3-ready oral immunotherapy targeting VEGFR-2.
The agreement could deliver up to $815 million in milestone payments to OSR Holdings, depending on future clinical, regulatory, and commercial achievements.
Agreement Gives BCM Europe Global Rights to VXM01
Under the deal, BCM Europe receives exclusive worldwide rights to develop, manufacture, commercialize, and potentially sublicense VXM01. The therapy is designed to support the immune system in targeting tumor blood vessels and changing the tumor microenvironment.
OSR Holdings said the agreement creates a clear framework for advancing VXM01 toward commercialization while aligning the interests of the company, BCM Europe, and public shareholders.
Key Financial Terms of the Transaction
The transaction includes milestone payments of up to $815 million. OSR Holdings will also acquire full intellectual property rights to VXM01 from Vaximm AG through a separate $30 million asset purchase agreement.
After BCM Europe recovers its investment and preferred return, OSR Holdings is expected to receive 100% of downstream royalties connected to VXM01.
BCM Europe Pledges Entire OSR Holdings Stake
A major part of the agreement is BCM Europeâs pledge of its full unencumbered equity stake in OSR Holdings as collateral. This stake represents about 29.7% of OSR Holdings as of the signing date.
The pledge is intended to strengthen confidence in BCM Europeâs milestone payment obligations and align the companyâs largest shareholder with public investors.
Related Party Transaction Reviewed by Independent Directors
Because BCM Europe is OSR Holdingsâ largest shareholder, the agreement is considered a related party transaction. OSR Holdings said its board, including independent directors, approved the transaction after reviewing an independent fairness opinion from Avance Life Sciences.
Put Option Adds Capital Flexibility
The agreement also includes a put option that may allow OSR Holdings to require BCM Europe to purchase up to $15 million of OSR Holdings common stock at $10.00 per share. This option can be exercised no earlier than six months after the effective date.
The company said this feature provides added financial flexibility and further shows BCM Europeâs long-term commitment to OSR Holdings.
About VXM01
VXM01 is a clinical-stage oral immunotherapy focused on VEGFR-2. It is being developed to trigger a targeted immune response against tumor vasculature, which may help limit tumor growth and improve treatment outcomes.
The therapy has shown encouraging clinical activity and immune activation in studies involving glioblastoma and pancreatic cancer, both of which are aggressive and difficult-to-treat solid tumors.
Strategic Importance for OSR Holdings
This agreement may become an important step for OSR Holdings as it works to advance biomedical innovation across immuno-oncology, regenerative biologics, and medical device technologies.
By securing milestone-based economics, royalty rights, and collateral backing from its largest shareholder, OSR Holdings aims to capture long-term value if VXM01 progresses successfully through development and commercialization.
Company Outlook
OSR Holdings noted that future results remain subject to clinical, regulatory, commercial, and market risks. The company also said forward-looking statements related to VXM01 and the agreement may differ from actual outcomes.
Still, the definitive license agreement gives OSR Holdings and BCM Europe a structured path to pursue global development, sublicensing opportunities, and potential commercialization of VXM01.
#OSRHoldings #VXM01 #Biotechnology #CancerImmunotherapy #SlimScan #GrowthStocks #CANSLIM